Mereo BioPharma Group plc
Close on Oct 19, 2026
- Market cap
- $242.76M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | – | $-0.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $500.00K | $-0.02 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.02 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.02 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | During market hours | – | – | – |
Press releases
Announcements Mereo BioPharma filed with the SEC
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K/A
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Provides Corporate Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mereo BioPharma J.P. Morgan Conference Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Provides Update on Lead Clinical Programs
Regulation FD disclosure · EX-99.1 to Form 8-K
Mereo BioPharma Reports Third Quarter 2024 Financial Results and
Material agreement · Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
Regulation FD disclosure · EX-99.1 to Form 8-K
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
EX-99.1 to Form 6-K
Condensed Consolidated Statements of Comprehensive Loss
EX-99.1 to Form 6-K
Ultragenyx Announces First Patients Dosed in Phase 3 Program
EX-99.1 to Form 6-K
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
EX-99.1 to Form 6-K
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
EX-99.1 to Form 6-K
Condensed Consolidated Statements of Comprehensive (Loss)/Income
EX-99.1 to Form 6-K
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
EX-99.1 to Form 6-K
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
EX-99.1 to Form 6-K
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
EX-99.1 to Form 6-K
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
EX-99.2 to Form 6-K